The FDA Group Insider Newsletter

Last updated: March 2026

These Terms & Conditions govern access to and use of The FDA Group Insider Newsletter (the “Newsletter”), published via Substack by The FDA Group.

By subscribing to or accessing paid content from the Newsletter, you agree to the terms outlined below.

1. Description of Service

The FDA Group Insider Newsletter is a digital publication delivered electronically via email and the Substack platform. Paid subscribers receive access to premium content, including but not limited to:

• Regulatory analysis and commentary

• FDA guidance breakdowns

• Warning letter analyses

• Industry news and insights

• Subscriber-only articles and resources

Content is delivered electronically via email and/or via the Substack website.

2. Subscription Billing

Paid subscriptions are billed in advance on a recurring basis depending on the plan selected at checkout (monthly or annual).

By subscribing, you authorize Substack and its payment processor to charge your selected payment method for the applicable subscription fee.

Subscription pricing is clearly displayed at the time of purchase.

3. Automatic Renewal

Subscriptions automatically renew at the end of each billing period unless cancelled prior to the renewal date.

Renewal charges will be processed using the payment method on file.

Subscribers may cancel their subscription at any time through their Substack account settings.

4. Cancellation Policy

Subscribers may cancel their subscription at any time.

Cancellation prevents future billing but does not result in a refund for the current billing period.

Subscribers will continue to have access to paid content until the end of the current billing cycle.

5. Refund Policy

Because the Newsletter provides immediate access to digital content, all subscription purchases are non-refundable once the subscription period has begun.

Refunds will not be issued for:

• Partially used subscription periods

• Failure to cancel prior to renewal

• Lack of use of the subscription

• Disputes initiated through a payment provider without first contacting support

In rare circumstances and at our sole discretion, we may issue refunds for billing errors.

Refund requests must be submitted to us directly before initiating a payment dispute.

6. Chargebacks and Payment Disputes

Subscribers agree to contact us directly to resolve any billing issues before initiating a chargeback or payment dispute with their bank or card issuer.

Initiating a chargeback after receiving access to paid digital content may constitute a violation of these Terms.

If a chargeback is filed after content has been delivered or accessed, we reserve the right to:

• Provide evidence of service delivery and usage to the payment processor

• Suspend or permanently revoke access to the Newsletter

• Block future purchases associated with the account or payment method

7. Delivery of Digital Content

All content provided through the Newsletter is delivered electronically via email and/or the Substack website.

Successful delivery of emails to the subscriber’s registered email address constitutes delivery of the service.

The FDA Group is not responsible for issues caused by:

• Spam filters

• Email provider restrictions

• User inbox configuration

• Failure to check the Substack website for content access

8. Intellectual Property

All content published in the Newsletter is the intellectual property of The FDA Group unless otherwise stated.

Paid subscription access grants a personal, non-transferable license to read the content.

Subscribers may not:

• Reproduce

• Distribute

• Republish

• Sell

• Share behind paywalls

any paid content without written permission.

9. Account Responsibility

Subscribers are responsible for maintaining the confidentiality of their account credentials.

Sharing paid access credentials or distributing subscriber-only content may result in account termination.

10. Modifications to the Service

The FDA Group reserves the right to modify the content, format, frequency, or availability of the Newsletter at any time.

Such modifications do not constitute grounds for refunds.

11. Limitation of Liability

The Newsletter is provided for informational purposes only.

The FDA Group does not guarantee the accuracy, completeness, or applicability of the information provided.

To the maximum extent permitted by law, The FDA Group shall not be liable for any damages resulting from use of the Newsletter.

12. Governing Law

These Terms & Conditions are governed by the laws of the United States.

Any disputes arising under these Terms shall be resolved in the appropriate jurisdiction.

13. Contact Information

For subscription or billing questions, please contact:

The FDA Group
Email: thefdagroup@substack.com